NK cell
- Generic Name
- NK cell
A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.
Phase 1
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML) RelapseNK Cell
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Not specified
- Target Recruit Count
- 12
- Registration Number
- NCT06641648
Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 35
- Registration Number
- NCT05171309
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath